Question 1: Review the results for the primary (PFS) and secondary endpoint (OS) from Choueiri 2021 for the comparison of Nivolumab & Cabozantinib vs Sunitinib. Construct a clinical conclusion (specific to efficacy) on the basis of the trial encompassing the key results and major factors that impact the interpretation.
Question 2: Given the clinical conclusion from Choueiri 2021 and the PBAC framework of decision making, what type of economic evaluation would be required and why is this approach justified?
Question 3: Review the results for the primary endpoint (Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at Week 48) from Sax 2012 for the comparison of ELV/c/TDF/FTC vs EFV/TDF/FTC. Construct a clinical conclusion (specific to efficacy) on the basis of the trial encompassing the key results and major factors that impact the interpretation.
Question 4: Given the clinical conclusion from Sax 2012 and the PBAC framework of decision making, what type of economic evaluation would be required and why is this approach justified?